TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have earned an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $34.43.

TGTX has been the topic of several recent research reports. The Goldman Sachs Group raised their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $49.00 price objective on shares of TG Therapeutics in a report on Wednesday, September 18th. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $50.00 price objective on the stock.

Institutional Trading of TG Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Opaleye Management Inc. boosted its stake in shares of TG Therapeutics by 2.9% in the 1st quarter. Opaleye Management Inc. now owns 2,280,000 shares of the biopharmaceutical company’s stock worth $34,679,000 after buying an additional 65,000 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of TG Therapeutics in the 2nd quarter worth approximately $36,501,000. Hood River Capital Management LLC boosted its stake in shares of TG Therapeutics by 6.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock worth $27,982,000 after buying an additional 98,892 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of TG Therapeutics in the 2nd quarter worth approximately $10,423,000. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of TG Therapeutics by 29.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 524,861 shares of the biopharmaceutical company’s stock worth $7,983,000 after buying an additional 120,699 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Trading Down 2.3 %

Shares of TGTX opened at $25.13 on Thursday. TG Therapeutics has a 52-week low of $7.17 and a 52-week high of $26.41. The business’s fifty day moving average is $23.44 and its 200-day moving average is $19.89. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of 109.26 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. During the same quarter last year, the company posted ($0.34) EPS. The company’s revenue for the quarter was up 357.0% compared to the same quarter last year. Equities analysts anticipate that TG Therapeutics will post 0.13 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.